TIDMOPTI

RNS Number : 2161I

OptiBiotix Health PLC

15 June 2017

15 June 2017

OptiBiotix Health plc

("OptiBiotix" or the Company")

Result of AGM

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol,

diabetes and skin care, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

 
 OptiBiotix Health plc                                                  www.optibiotix.com 
 Stephen O'Hara, Chief Executive                                               Contact via 
                                                                            Walbrook below 
 
 Cairn Financial Advisers LLP (NOMAD)                                        Tel: 020 7213 
                                                                                      0880 
 Liam Murray / Jo Turner 
 
   finnCap (Broker)                                                          Tel: 020 7220 
                                                                                      0500 
 Adrian Hargrave / Scott Mathieson 
  / Kate Bannatyne (Corporate Finance) 
 Tony Quirke (Corporate Broking) 
 
 Walbrook PR Ltd                           Tel: 020 7933 8780 or optibiotix@walbrookpr.com 
 Anna Dunphy                                                                Mob: 07876 741 
                                                                                       001

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen(R) and OptiBiotic(R) platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGFAMBTMBTBBPR

(END) Dow Jones Newswires

June 15, 2017 07:30 ET (11:30 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Optibiotix Health Charts.